ALBIO — Biosynex SA Income Statement
0.000.00%
Last trade - 00:00
- €50.98m
- €81.47m
- €196.59m
- 40
- 68
- 14
- 32
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | FAS | FAS | FAS | FAS | FAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 31.2 | 34.2 | 154 | 383 | 197 |
Cost of Revenue | |||||
Gross Profit | 16.2 | 19.5 | 69.3 | 206 | 102 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 30.7 | 33.3 | 109 | 243 | 164 |
Operating Profit | 0.518 | 0.965 | 44.7 | 140 | 32.9 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0.371 | 0.9 | 44.4 | 140 | 29.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.543 | 1.12 | 32.2 | 107 | 21.2 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 0.543 | 1.12 | 31.4 | 104 | 15.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.543 | 1.12 | 31.4 | 104 | 15.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.026 | 0.134 | 3.48 | 9.41 | 2.49 |
Dividends per Share |